Molecular diagnosis of pancreatic cancer: Where do we stand?

Emanuele Lo Menzo, Maria Di Vita, Massimiliano Berretta, Pierfrancesco Veroux, Antonio Zanghì, Andrea Cavallaro, Bruno Cacopardo, Alessandro Cappellani

Research output: Contribution to journalArticlepeer-review


Pancreatic cancer remains a disease with a dismal prognosis due mostly to its late diagnosis. An early diagnosis would have a significant impact on the prognosis and, eventually, on the incidence of the disease itself. Many progresses have been made in the molecular diagnosis of pancreatic cancer. High risk patients would likely benefits from biologic screening, before the general population. Most of the markers remain limited to phase I and II studies. The challenges include the lack of specificity of some of the markers, as well as the lack of standardization within the laboratories. Further research is necessary prior to the application of the currently known biomarkers for the diagnosis of pancreatic cancer.

Original languageEnglish
Pages (from-to)578-590
Number of pages13
JournalFrontiers in Bioscience - Scholar
Volume2 S
Issue number2
Publication statusPublished - Jan 1 2010


  • Follow up
  • IPMN
  • Markers
  • Pancreatic cancer
  • Prognosis
  • Review
  • Screening

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)


Dive into the research topics of 'Molecular diagnosis of pancreatic cancer: Where do we stand?'. Together they form a unique fingerprint.

Cite this